Insulin Degludec Injection, Solution
Product Images NDC 73070-403

Product Visual Gallery

This gallery contains 63 technical images submitted to the FDA as part of the official labeling for Insulin Degludec (NDC 73070-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Tresiba (Image 01)

Chemical structure diagram of insulin degludec, showing the amino acid sequence and molecular components labeled with positions A1 to A29 and B1 to B29, including side chains and structural modifications.*

FDA Label Image

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)

A line graph depicting glucose infusion rate (GIR) over time since injection (hours) for insulin degludec at 0.4 U/kg. The graph shows GIR values from 0 to 42 hours, with a shaded area highlighting the initial 24-hour interval.*

FDA Label Image

Vial Ifu-1 (Image 03)

An illustration of a vial with a tamper-resistant cap featuring a rubber stopper under the cap, designed for an injection solution vial.*

FDA Label Image

Vial Ifu-2 (Image 04)

An instructional illustration showing a hand holding a small vial, presumably of insulin degludec injection solution, indicating how to hold the vial for use.*

FDA Label Image

Vial Ifu-figure A,b (Image 05)

Instructional illustration showing two steps for preparing a medication injection. The first step depicts a hand removing a cap from a vial or cartridge. The second step shows holding the vial and preparing to attach a needle or injection device. No specific product branding or labels are visible.*

FDA Label Image

Vial Ifu-figure C (Image 06)

An instructional illustration showing how to prepare an injection using a syringe and vial. It depicts one hand holding the vial and another inserting the syringe needle into the vial with a downward arrow indicating the motion.*

FDA Label Image

Vial Ifu-figure D (Image 07)

An instructional illustration showing a hand twisting or connecting a needle to an insulin injection pen. The image demonstrates the step of attaching the needle to the pen device for subcutaneous injection.*

FDA Label Image

Vial Ifu-figure E (Image 08)

An instructional diagram showing how to attach a needle to a syringe by holding the syringe with one hand and the needle with the other while aligning them for connection. The illustration is simple and uses line art with arrows indicating the direction of attachment.*

FDA Label Image

Vial Ifu-figure F (Image 09)

Illustration showing the proper technique to remove air bubbles from a syringe filled with insulin degludec solution for subcutaneous injection, depicting a hand holding the syringe upright with an arrow pointing downward.*

FDA Label Image

Vial Ifu-figure G (Image 10)

An instructional illustration showing a hand holding a vial or pen device for subcutaneous injection, with the other hand positioned to prepare or administer the injection. The image likely demonstrates proper handling or injection technique for insulin degludec injection solution.*

FDA Label Image

Vial Ifu-figure H (Image 11)

An instructional illustration depicting the preparation of an injection syringe. The image shows a hand holding a vial upside down and inserting a needle into it. An inset zooms in on the needle inserted into the vial's rubber stopper, emphasizing correct technique. No text or branding visible.*

FDA Label Image

Vial Ifu-figure I (Image 12)

An instructional illustration depicting a hand holding an injection pen for subcutaneous administration and a vial of medication with an arrow indicating the connection of the needle to the pen. The image is related to the preparation or administration of Insulin Degludec injection solution.*

FDA Label Image

Vial Ifu-figure J (Image 13)

An anatomical illustration showing front and back views of a human body with highlighted areas for subcutaneous injection sites, including the abdomen, thighs, buttocks, and upper arms. This diagram is relevant for subcutaneous injection of medications such as insulin degludec.*

FDA Label Image

Vial Ifu-figure K (Image 14)

An instructional illustration showing the proper technique for a subcutaneous injection. It depicts a hand holding a syringe poised to inject into the skin of the opposite forearm, with an arrow indicating the angle of insertion.*

FDA Label Image

Vial Ifu-figure L (Image 15)

An instructional illustration showing a hand holding a syringe or injection pen above an exposed forearm, with an arrow indicating an upward motion, suggesting the technique for subcutaneous injection.*

FDA Label Image

Figure A: Novofine Needle Components (Image 16)

An instructional diagram labeled "NovoFine" showing four components of an injection needle assembly: outer needle cap, inner needle cap, needle, and a paper tab, arranged from left to right.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 17)

An instructional diagram showing components of the NovoTwist device parts: an outer needle cap, inner needle cap, needle, and paper tab. Each part is labeled and displayed separately in a sequence from left to right.*

FDA Label Image

Figure A (Image 18)

An illustration of an Insulin Degludec Injection FlexTouch pen showing labeled parts: pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen is designed for subcutaneous injection and single patient use.*

FDA Label Image

100 U/ml Ifu (Figure B)

An instructional illustration showing the proper method for handling a pen-type injector device, specifically demonstrating how to pull off the yellow protective cap, likely related to administration of Insulin Degludec injection solution.*

FDA Label Image

100 U/ml Ifu (Figure C)

An instructional illustration showing a hand holding an insulin pen with a needle cap attached at the end. The image highlights the proper grip and positioning of the pen for subcutaneous injection of insulin degludec.*

FDA Label Image

100 U/ml Ifu (Figure D)

Illustration showing the use of NovoFine and NovoTwist pen needles, with arrows indicating the direction to unscrew or remove the needle from the pen device, demonstrating proper needle removal technique.*

FDA Label Image

100 U/ml Ifu (Figure E)

An instructional illustration showing how to attach the NovoFine needle to the NovoTwist pen device for insulin injection. The image depicts a hand aligning and securing the needle onto the pen injector, with each step labeled as NovoFine and NovoTwist.*

FDA Label Image

100 U/ml Ifu (Figure F)

Instructional illustration showing the use of NovoFine and NovoTwist needles with an insulin injection pen. The image depicts hands attaching or preparing the needle for subcutaneous injection, highlighting proper connection technique for insulin administration.*

FDA Label Image

100 U/ml Ifu (Figure G)

An instructional illustration showing how to connect a NovoFine or NovoTwist needle to a syringe or pen device. The image features a close-up of a hand attaching the needle, with arrows indicating the direction of connection.*

FDA Label Image

100 U/ml Ifu (Figure H)

An illustration showing a close-up of a hand adjusting a dose selector on an insulin pen. The dose window displays "2 units selected," and the thumb is positioned to turn the dial on the pen, emphasizing dose selection for insulin injection.*

FDA Label Image

100 U/ml Ifu (Figure I)

An instructional illustration showing a hand holding a pen-like injector device with a visible liquid reservoir, indicating preparation or use of a subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure J)

An instructional illustration showing a hand holding an insulin degludec injection pen, demonstrating the removal of the cap by pulling it upwards. A zoomed inset highlights the pen's capped top being lifted off.*

FDA Label Image

100 U/ml Ifu (Figure K)

An instructional illustration showing a close-up of the dosing dial of an insulin pen for insulin degludec injection. The image demonstrates selecting specific dose units on the pen, with example numbers '5 units' and '24 units' highlighted on the dial to indicate how to adjust the injection dose.*

FDA Label Image

100 U/ml Ifu (Figure L)

An instructional illustration showing a syringe with an insulin solution, marked with dose levels and an example indicating approximately 200 units left in the syringe. This image is likely used to demonstrate insulin measurement or injection technique for insulin degludec injection, solution 100 U/mL or 200 U/mL by Novo Nordisk Pharma, Inc.*

FDA Label Image

100 U/ml Ifu (Figure M)

Illustration showing front and back views of a human body with highlighted areas for subcutaneous injection sites, including the abdomen, upper arms, front and back of thighs, and buttocks.*

FDA Label Image

100 U/ml Ifu (Figure N)

An instructional illustration showing a hand holding a pen-like injector device filled with a yellow solution. An arrow points downward below the device, indicating a direction or step in the injection process, likely subcutaneous administration of insulin degludec.*

FDA Label Image

100 U/ml Ifu (Figure O)

An instructional illustration showing a hand holding an insulin injection pen with an arrow indicating to press or push down on the top part of the pen to administer the dose. A small gauge or dial is visible on the pen's side.*

FDA Label Image

100 U/ml Ifu (Figure P)

An instructional diagram showing a hand holding an insulin vial or cartridge with yellow liquid inside, accompanied by a speech bubble with the numbers 1-2-3-4-5-6, illustrating the action to count slowly, likely as part of the medication's preparation or administration steps.*

FDA Label Image

100 U/ml Ifu (Figure Q)

An instructional illustration showing a subcutaneous insulin injection device with an arrow pointing upward, indicating the direction to pull or remove the needle cap from the insulin pen.*

FDA Label Image

100 U/ml Ifu (Figure R)

An instructional diagram showing two steps for the NovoFine and NovoTwist pen needles used with insulin injection devices. The left panel illustrates attaching or aligning the NovoFine needle with a rightward arrow, and the right panel shows removing or detaching the NovoTwist needle with an upward arrow, both depicted on pen needle caps attached to the injection device.*

FDA Label Image

100 U/ml Ifu (Figure S)

An instructional diagram showing the steps to attach a gray protective cap to the needle end of a syringe containing insulin degludec injection solution. The arrows indicate the direction to push the cap onto the syringe plunger end to secure it.*

FDA Label Image

100 U/ml Ifu (Figure T)

An instructional illustration showing a close-up of hands handling a pen-type injection device, specifically depicting the removal or attachment of a yellow cap or needle cover, representing a step in preparing an insulin injection.*

FDA Label Image

U200 Figure A (Image 38)

Illustration of an Insulin Degludec injection pen showing its parts labeled, including the pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen label indicates it is FlexTouch for single-patient use with a strength of 200 units/mL.*

FDA Label Image

Vial Carton (Image 39)

Insulin Degludec injection solution packaging label by Novo Nordisk Pharma, Inc. It contains 100 units/mL (U-100) strength for subcutaneous use only. The label indicates it is a prescription product available in a 10 mL multiple-dose vial. It includes storage instructions and barcode.*

FDA Label Image

Figure A: Novofine Needle Components (Image 40)

Illustration showing the components of a NovoFine needle assembly including the outer needle cap, inner needle cap, needle, and paper tab. The diagram displays each piece separately in a left-to-right sequence.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 41)

An instructional illustration labeled NovoTwist depicting four components: outer needle cap, inner needle cap, needle, and paper tab. Each component is shown separately to demonstrate assembly or usage steps, likely related to a syringe or injection device.*

FDA Label Image

Ft U100 (Image 42)

Insulin Degludec Injection FlexTouch pen packaging label showing 100 units/mL strength in a 3x3 mL prefilled pen format. The label includes the Novo Nordisk Pharma, Inc. logo and emphasizes single patient use. It includes warnings about insulin use, storage instructions, and tamper evidence details, with blue and green text and graphics on a white background.*

FDA Label Image

200 U/ml Ifu Figure B (Image 43)

An instructional illustration showing a close-up of hands twisting or removing a green cap or protective cover from a cylindrical object, likely related to the administration of an injectable insulin product.*

FDA Label Image

200 U/ml Ifu Figure C (Image 44)

An instructional diagram illustrating a close-up view of a medication pen injector, highlighting the injection needle area with a protective cap, commonly used for subcutaneous administration of insulin degludec.*

FDA Label Image

200 U/ml Ifu Figure D (Image 45)

Illustration showing a close-up of hands preparing a NovoFine or NovoTwist needle for injection, with arrows indicating the correct direction to remove the needle cap. The image is related to the assembly or use of injection needles for insulin administration.*

FDA Label Image

200 U/ml Ifu Figure E (Image 46)

An instructional illustration demonstrating how to prepare an injection pen for use, labeled with NovoFine and NovoTwist. The image shows hands holding the pen and twisting the needle attachment to secure it before injection.*

FDA Label Image

200 U/ml Ifu Figure F (Image 47)

An instructional illustration displaying the use of NovoFine and NovoTwist needles for subcutaneous injection. It shows an arrow indicating the direction to attach or twist the needle onto the syringe, demonstrating proper assembly technique for injection devices.*

FDA Label Image

200 U/ml Ifu Figure G (Image 48)

Instructional diagram showing two methods for attaching a needle to a syringe pen: NovoFine and NovoTwist. The image illustrates hand placement and directional motion for each technique using arrows, depicting how to properly connect the needle before use.*

FDA Label Image

200 U/ml Ifu Figure H (Image 49)

An instructional illustration showing the selection of insulin dosage on a dial. The image depicts fingers turning a dial with a display window indicating '2 units selected,' likely for subcutaneous injection dosage adjustment of Insulin Degludec.*

FDA Label Image

Ft U200 (Image 50)

Insulin Degludec Injection FlexTouch prefilled pen packaging label showing 200 units/mL (U-200) strength. The label includes product name Insulin Degludec, administration route subcutaneous injection, and specifies single patient use. It also features dosage instructions, manufacturer Novo Nordisk Pharma, Inc., and warnings about storage conditions and patient use restrictions.*

FDA Label Image

Figure 3 (Image 52)

A line graph comparing the percentage of subjects experiencing an event over time in months for two insulin treatments: Insulin Degludec (IDeg) and Insulin Glargine (IGlar). The x-axis represents time to first event (months) and the y-axis shows the percentage of subjects with an event. The graph includes a hazard ratio with 95% confidence interval.*

FDA Label Image

200 U/ml Ifu Figure I (Image 53)

An instructional diagram showing a hand holding an insulin degludec pen injector. The illustration emphasizes the action of pressing the top of the pen, likely to prepare or administer the injection. The pen is depicted in green with detailing to indicate its structure.*

FDA Label Image

200 U/ml Ifu Figure J (Image 54)

An instructional illustration showing a hand holding an insulin pen injection device, with the cap being removed by pulling it upward. The image highlights proper handling of the insulin injection device prior to subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure K (Image 55)

An instructional illustration showing how to select dosing units on an insulin injection device for Insulin Degludec. It demonstrates a hand adjusting the dose by rotating the dial from 6 units to 24 units, with visual examples of the dose indicators on the device's display window.*

FDA Label Image

200 U/ml Ifu Figure L (Image 56)

Illustration of an insulin pen cartridge showing a close-up of the dosing window marked with units from 0 to 100, indicating an example dose of approximately 400 units left. The image highlights the cartridge’s volume measurement and needle attached at the top, typically used for subcutaneous injection of insulin degludec.*

FDA Label Image

200 U/ml Ifu Figure M (Image 57)

An instructional diagram showing front and back views of a human body indicating recommended subcutaneous injection sites in the abdominal, thigh, and upper arm areas for insulin administration.*

FDA Label Image

200 U/ml Ifu Figure N (Image 58)

An instructional illustration showing a hand holding an insulin pen injector vertically with the thumb positioned near the top and an arrow pointing downward. This image demonstrates how to correctly hold the insulin degludec injection pen for subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure O (Image 59)

An instructional illustration showing a hand holding a syringe-like pen device with a downward arrow indicating the direction. Inset shows a close-up of a dial set to 0, likely related to dose setting or preparation steps for injection.*

FDA Label Image

200 U/ml Ifu Figure P (Image 60)

An instructional illustration showing a hand holding a syringe or pen device for injection. The speech bubble instructs to "Count slowly: 1-2-3-4-5-6," indicating a slow count during the injection process. This diagram is likely part of patient guidance for subcutaneous injection technique.*

FDA Label Image

200 U/ml Ifu Figure Q (Image 61)

An instructional illustration showing an insulin degludec injection pen with an upward-pointing arrow, indicating the direction to hold or move the pen during use.*

FDA Label Image

200 U/ml Ifu Figure R (Image 62)

An instructional illustration showing the use of NovoFine and NovoTwist pen needles for injection. The left panel (NovoFine) depicts rotating the needle onto the pen with a twisting motion, while the right panel (NovoTwist) shows lifting the needle straight up to remove or attach it.*

FDA Label Image

200 U/ml Ifu Figure S (Image 63)

An instructional illustration showing the removal of a green syringe cap by pulling it straight off. The image uses arrows to indicate the direction for detaching the cap from an injection device, likely demonstrating part of the preparation steps for subcutaneous injection.*

FDA Label Image

200 U/ml Ifu Figure T (Image 64)

An instructional illustration showing hands removing a cap or cover, likely from a pen or injector device tip, suggesting preparation steps for subcutaneous injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.